Gastrointestinal Motility in Patients With Neuroendocrine Tumors

University of Aarhus

Status: Completed

Conditions: Neuroendocrine Tumor

Treatments: Device: Magnetic Tracking System (MTS) and radio-opaque markers

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00789841

M-20080121

Details and patient eligibility

About

We will study the total gastrointestinal transit time (GITT), gastric emptying and small intestine motility in NET patients before and after treated with somatostatin analogues and compare these to healthy subjects. For this we will use radio-opaque markers and the newly developed Motility Tracking System (MTS).

Hypothesis: Patients with NET and carcinoid syndrome have decreased GITT, gastric emptying and small bowel transit time and an increase in phase III MMC activity compared to healthy subjects. Treatment with somatostatin analogues increase transit times and decrease phase III MMC activity and improves the clinical symptoms.

Enrollment: 13 patients

Sex: All

Ages: 30 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• NET confirmed by histology
• Diarrhea, (at least 3 loose or watery bowel movements per day) as part of carcinoid syndrome.
• Newly referred patients without previous somatostatin analogue treatment or
• NET patients who are pausing somatostatin analogue treatment due to other treatment or examination.

Exclusion criteria

• Subjects unable to understand the information
• Severe diabetes with late complications or known metabolic disorder
• Inflammatory bowel disease
• Known clinically significant stenosis of the bowel
• Bile acid malabsorption due to intestinal surgery
• Small bowl bacterial overgrowth

Trial design

13 participants in 1 patient group

Patients with NET and diarrhea.

Treatment:

Device: Magnetic Tracking System (MTS) and radio-opaque markers